<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902025000301207</article-id>
<article-id pub-id-type="doi">10.29193/rmu.41.3.7</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Toma de decisiones en cáncer de próstata: un análisis de la influencia y significado de los comités de tumores en una cohorte de pacientes tratados con radioterapia o prostatectomía]]></article-title>
<article-title xml:lang="en"><![CDATA[Decision-making in prostate cancer: an analysis of the influence and significance of tumor boards in a cohort of patients treated with radiotherapy or prostatectomy]]></article-title>
<article-title xml:lang="pt"><![CDATA[Tomada de decisão no câncer de próstata: uma análise da influência e significado dos comitês de tumores em uma coorte de pacientes tratados com radioterapia ou prostatectomia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jeldres]]></surname>
<given-names><![CDATA[Mathias]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silveyra]]></surname>
<given-names><![CDATA[Noelia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vitureira]]></surname>
<given-names><![CDATA[Florencia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[Ana Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Krygier]]></surname>
<given-names><![CDATA[Gabriel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital de Clínicas Servicio de Oncología Clínica ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Servicio Médico Integral  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>41</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902025000301207&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902025000301207&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902025000301207&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: el cáncer de próstata es el de mayor incidencia en Uruguay. Se caracteriza por una gran heterogeneidad clínica y biológica. En los estadios localizados, los tratamientos radicales con cirugía o radioterapia acompañados del tratamiento hormonal logran excelentes resultados en la mayoría de los pacientes. Sin embargo, no existe evidencia de resultados nacionales en cuanto los resultados de estos tratamientos. En este trabajo se evaluaron retrospectivamente las características epidemiológicas y la eficacia de los tratamientos en una cohorte de pacientes de una institución mutual nacional, así como el impacto de la toma de decisiones en los comités de tumores.  Objetivos: analizar las características clínico-epidemiológicas y realizar un análisis de eficacia de tratamientos en una cohorte de pacientes portadores de cáncer de próstata en el Servicio de Oncología del Servicio Médico Integral (SMI) en un período de 4 años.  Materiales y métodos: se realizó un estudio descriptivo, observacional y retrospectivo, con base en la revisión de historias clínicas de 147 pacientes con diagnóstico de cáncer de próstata asistidos en el SMI.  Resultados: en este estudio descriptivo, se analizaron 147 pacientes con cáncer de próstata, destacando el enfoque multidisciplinario en la gestión de estos casos. El 100 % de los tratamientos fueron discutidos en un comité de tumores, evidenciando una práctica integral. La mayoría de los pacientes (87 %) presentaban la enfermedad en estadios localizados al debut, con una mediana de 67 años. Las evaluaciones diagnósticas incluyeron el tacto rectal, dosificación de PSA y pruebas de imagen convencionales. Los tratamientos para estadios localizados variaron entre radioterapia, prostatectomía radical y vigilancia activa, seleccionados según criterios clínicos. Se observó una baja tasa de recaída en el seguimiento a dos años, especialmente en pacientes bajo vigilancia activa. La discusión de casos en comités especializados fue esencial para la toma de decisiones terapéuticas. La supervivencia libre de enfermedad (SLE) a 5 años no mostró diferencias significativas entre radioterapia y prostatectomía radical, con una tasa del 82 %. La aparición de segundos tumores fue del 12 %, siendo el más común el tumor de riñón. La edad y el estadio de la enfermedad influyeron en la elección terapéutica y en los resultados.  Conclusión: este estudio subraya la importancia de la discusión multidisciplinaria, la adaptabilidad de los tratamientos y la necesidad de una atención continua en el cáncer de próstata en Uruguay.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: prostate cancer has the highest incidence among cancers in Uruguay. It is characterized by significant clinical and biological heterogeneity. In localized stages, radical treatments with surgery or radiotherapy, often combined with hormonal therapy, achieve excellent outcomes in most patients. However, there is no national evidence on the outcomes of these treatments. This study retrospectively evaluated the epidemiological characteristics and treatment efficacy in a cohort of patients from a national mutual healthcare institution, as well as the impact of decision-making through tumor boards.  Objectives: to analyze the clinical and epidemiological characteristics and assess treatment efficacy in a cohort of prostate cancer patients managed by the Oncology Department of Servicio Médico Integral (SMI) over a four-year period.  Materials and methods: a descriptive, observational, and retrospective study was conducted based on the review of medical records from 147 patients diagnosed with prostate cancer and treated at SMI.  Results: In this descriptive study, 147 prostate cancer patients were analyzed, emphasizing the multidisciplinary approach to case management. All treatment decisions (100%) were discussed in a tumor board, reflecting an integrated care model. Most patients (87%) presented with localized disease at diagnosis, with a median age of 67 years. Diagnostic evaluations included digital rectal examination, PSA testing, and conventional imaging. Treatment options for localized stages included radiotherapy, radical prostatectomy, and active surveillance, selected based on clinical criteria. A low recurrence rate was observed at two-year follow-up, particularly among patients under active surveillance. Tumor board discussions played a key role in therapeutic decision-making. Five-year disease-free survival (DFS) showed no significant differences between radiotherapy and radical prostatectomy, with an overall rate of 82%. The incidence of second primary tumors was 12%, with kidney cancer being the most common. Age and disease stage influenced both treatment choice and outcomes.  Conclusion: this study highlights the importance of multidisciplinary discussion, the adaptability of treatment approaches, and the need for continuous care in the management of prostate cancer in Uruguay.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução: o câncer de próstata é o de maior incidência no Uruguai, caracterizando-se por uma grande heterogeneidade clínica e biológica. Nos estágios localizados, os tratamentos radicais com cirurgia ou radioterapia, associados à terapia hormonal, alcançam excelentes resultados na maioria dos pacientes. No entanto, não há evidências nacionais sobre os resultados desses tratamentos. Neste estudo, foram avaliadas retrospectivamente as características epidemiológicas e a eficácia dos tratamentos em uma coorte de pacientes atendidos em uma instituição mutualista nacional, bem como o impacto da tomada de decisão nos comitês de tumores.  Objetivos: analisar as características clínico-epidemiológicas e realizar uma análise da eficácia dos tratamentos em uma coorte de pacientes com câncer de próstata atendidos no Serviço de Oncologia do Serviço Médico Integral (SMI) ao longo de um período de quatro anos.  Materiais e Métodos: foi realizado um estudo descritivo, observacional e retrospectivo, com base na revisão dos prontuários de 147 pacientes diagnosticados com câncer de próstata atendidos no SMI.  Resultados: Neste estudo descritivo, foram analisados 147 pacientes com câncer de próstata, com destaque para a abordagem multidisciplinar na condução dos casos. Todos os tratamentos (100%) foram discutidos em comitês de tumores, evidenciando uma prática assistencial integrada. A maioria dos pacientes (87%) apresentava a doença em estágios localizados no momento do diagnóstico, com mediana de idade de 67 anos. As avaliações diagnósticas incluíram o exame digital retal, dosagem de PSA e exames de imagem convencionais. Os tratamentos para estágios localizados variaram entre radioterapia, prostatectomia radical e vigilância ativa, sendo escolhidos conforme critérios clínicos. Observou-se uma baixa taxa de recidiva no acompanhamento de dois anos, especialmente entre os pacientes sob vigilância ativa. A discussão dos casos em comitês especializados foi essencial para a tomada de decisão terapêutica. A sobrevida livre de doença (SLD) em cinco anos não apresentou diferenças significativas entre radioterapia e prostatectomia radical, com uma taxa de 82%. A incidência de segundos tumores foi de 12%, sendo o mais comum o tumor renal. A idade e o estágio da doença influenciaram na escolha do tratamento e nos desfechos.  Conclusão: este estudo ressalta a importância da discussão multidisciplinar, da adaptabilidade das abordagens terapêuticas e da necessidade de um acompanhamento contínuo no tratamento do câncer de próstata no Uruguai.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer]]></kwd>
<kwd lng="es"><![CDATA[Cáncer de próstata]]></kwd>
<kwd lng="es"><![CDATA[Comité de tumores]]></kwd>
<kwd lng="es"><![CDATA[Radioterapia]]></kwd>
<kwd lng="es"><![CDATA[Hormonoterapia]]></kwd>
<kwd lng="es"><![CDATA[Prostatectomía]]></kwd>
<kwd lng="en"><![CDATA[Cancer]]></kwd>
<kwd lng="en"><![CDATA[Prostate cancer]]></kwd>
<kwd lng="en"><![CDATA[Tumor board]]></kwd>
<kwd lng="en"><![CDATA[Radiotherapy]]></kwd>
<kwd lng="en"><![CDATA[Hormone therapy]]></kwd>
<kwd lng="en"><![CDATA[Prostatectomy]]></kwd>
<kwd lng="pt"><![CDATA[Câncer]]></kwd>
<kwd lng="pt"><![CDATA[Câncer de próstata]]></kwd>
<kwd lng="pt"><![CDATA[Comitê de tumores]]></kwd>
<kwd lng="pt"><![CDATA[Radioterapia]]></kwd>
<kwd lng="pt"><![CDATA[Hormonoterapia]]></kwd>
<kwd lng="pt"><![CDATA[Prostatectomia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="">
<collab>IARC Global Cancer Observatory</collab>
<source><![CDATA[Prostate Cancer - Statistics]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="">
<collab>Comisión Honoraria de Lucha contra el Cáncer</collab>
<source><![CDATA[Situación Epidemiológica del Uruguay en relación al Cáncer]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McLain Kase]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progression free survival in patients with castrate resistant metastatic prostate cancer: does sequence matter?]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2018</year>
<volume>36</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>365</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamdy]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Donovan]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Metcalfe]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2023</year>
<volume>388</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1547-58</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D&#8217;Amico]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Whittington]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Malkowicz]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1998</year>
<volume>280</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>969-74</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="">
<source><![CDATA[Software GraphPad Prism versión 9.4.1 (458)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El Saghir]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Keating]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Carlson]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Khoury]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Fallowfield]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide]]></article-title>
<source><![CDATA[Am Soc Clin Oncol Educ Book]]></source>
<year>2014</year>
<page-range>461-6</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Specchia]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Frisicale]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Carini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of tumor board on cancer care: evidence from an umbrella review]]></article-title>
<source><![CDATA[BMC Health Serv Res]]></source>
<year>2020</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Programa de Prevención de Enfermedades no transmisibles (PPENT)]]></source>
<year></year>
<publisher-name><![CDATA[Segunda Encuesta Nacional de Factores de Riesgo de Enfermedades no Transmisibles]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hofman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrentschuk]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vela]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
<volume>395</volume>
<numero>10231</numero>
<issue>10231</issue>
<page-range>1208-16</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gleason]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Mellinger]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>1974</year>
<volume>111</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>58-64</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Egevad]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Amin]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Delahunt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Srigley]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Humphrey]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system]]></article-title>
<source><![CDATA[Am J Surg Pathol]]></source>
<year>2016</year>
<volume>40</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>244-52</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ni]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients]]></article-title>
<source><![CDATA[Prostate]]></source>
<year>2021</year>
<volume>81</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>721-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Gabel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schreiber]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2020</year>
<volume>126</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>506-14</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shore]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Morgans]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[El Haddad]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Srinivas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abramowitz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Challenges and controversies in the management of prostate cancer with multidisciplinary teams]]></article-title>
<source><![CDATA[Target Oncol]]></source>
<year>2022</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>709-25</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamel]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Khalil]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Alobuia]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of metastasis and prostate-specific antigen levels at diagnosis in Gleason 3+4 versus 4+3 prostate cancer]]></article-title>
<source><![CDATA[Urol Ann]]></source>
<year>2018</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>203-08</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eastham]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Auffenberg]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Barocas]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Chou]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Crispino]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinically localized prostate cancer: AUA/ASTRO Guideline. Part III: principles of radiation and future directions]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2022</year>
<volume>208</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-33</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wallis]]></surname>
<given-names><![CDATA[CJD]]></given-names>
</name>
<name>
<surname><![CDATA[Mahar]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Choo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Herschorn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kodama]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2016</year>
<volume>352</volume>
<page-range>i851</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aksnessæther]]></surname>
<given-names><![CDATA[BY]]></given-names>
</name>
<name>
<surname><![CDATA[Myklebust]]></surname>
<given-names><![CDATA[TÅ]]></given-names>
</name>
<name>
<surname><![CDATA[Solberg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Klepp]]></surname>
<given-names><![CDATA[OH]]></given-names>
</name>
<name>
<surname><![CDATA[Skovlund]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hoff]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Second cancers in patients with locally advanced prostate cancer randomized to lifelong endocrine treatment with or without radical radiation therapy: long-term follow-up of the Scandinavian prostate cancer group-7 trial]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2020</year>
<volume>106</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>706-14</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
